Asthma; Eosinophilic
Conditions
Brief summary
The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .
Interventions
PROCEDUREBlood Punction
venous blood sampling
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma * Signature of informed consent * Affiliation with the French social security system
Exclusion criteria
* Non-eosinophilic asthma * Coexistence of a chronic eosinophilic inflammatory condition other than asthma * Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.) * Treatment with corticosteroids within 10 days prior to inclusion * Active smoking or a smoking history of more than 20 pack-years * Pregnant women * Legal incapacity or limited legal capacity * Subject unlikely to cooperate with the study and/or with anticipated low cooperation as assessed by the investigator * Subject without health insurance * Subject currently in an exclusion period of another study or as indicated by the national registry of volunteers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Flow cytometry based eosinophil phenotyping : Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity) | at inclusion | Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity) |
Contacts
Primary ContactCindy Barnig, MD, PhD
Outcome results
None listed